ELVN
Enliven Therapeutics, Inc.
Key Financials
Net Income
$-103694000
↓ 16.5%
Operating Income
$-119658000
↓ 14.4%
EPS (Diluted)
$-1.83
↑ 3.2%
Total Assets
$476.2M
↑ 46.2%
Shareholders' Equity
$459.6M
↑ 48.3%
Total Liabilities
$16.6M
↑ 4.1%
Cash & Equivalents
$98.9M
↓ 20.3%
Operating Cash Flow
$-70301000.00
↑ 3.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 144 | 6/15/2026 | View on SEC |
| 144 | 6/15/2026 | View on SEC |
| 144 | 6/15/2026 | View on SEC |
| 8-K | 6/12/2026 | View on SEC |
| 424B5 | 6/12/2026 | View on SEC |
| 424B5 | 6/11/2026 | View on SEC |
| 8-K | 6/11/2026 | View on SEC |
| 8-K | 6/10/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
| 144 | 6/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ELVN |
| Company Name | Enliven Therapeutics, Inc. |
| CIK | 1672619 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 720-647-8519 |